|
Livzan M.A., Bikbavova G.R., Safiulina T.A., Loginova E.N.
Gut microbiome modulation and cardiovascular risks: Mechanisms of formation and correction
|
№8 / 2023
|
|
Tarasova L.V., Kucherova N.Yu.
A case of atherotrombotic variant of ischemic stroke in Crohn’s disease patient
|
№7 / 2023
|
|
Boeva O.I., Kokorin V.A., Latiy V.V.
Lipid-lowering therapy today and tomorrow
|
№4 / 2023
|
|
Shushanova A.S., Gladkikh N.N., Yagoda A.V.
Myocardial infarction type 1 at young age: Contribution of proatherogenic factors and genetic thrombophilies
|
№4 / 2023
|
|
Alieva A.M., Teplova N.V., Ettinger O.A., Reznik E.V., Baykova I.E., Sarakaeva L.R., Shnahova L.M., Arakelyan R.A., Valiev R.K., Nikitin I.G.
The role of interleukin 12 in the development of cardiovascular diseases
|
№6 / 2022
|
|
Polyakov V.Ya., Kovrigin I.I., Kozhin P.M., Nikolaev Yu.A., Malov A.S., Sevostyanova E.V., Menschikova E.B.
Features of the relationship between clinical and laboratory, ultrasound signs of atherosclerosis and antioxidant defense in patients with comorbid pathology
|
№9 / 2021
|
|
Fedulaev Yu.N., Klykov L.L., Lebedeva A.Yu., Shoshina I.N., Makarova I.V., Pinchuk T.V.
QT dispersion: another way to diagnose coronary artery disease
|
№4 / 2021
|
|
Heylo T.S., Danilogorskaya Yu.A., Nazarenko G.B., Martynov A.I.
Estimation of the influence of 6 week therapy by meldonium (Mildronate®) at bulbar capillaroscopy indexes in chronic ischemic heart and brain disease female patient
|
№3 / 2020
|
|
Ju.V. Lukina
Atherosclerosis and comorbidity
|
№4 / 2018
|
|
A.N. Meshkov
Evolocumab – a new medicine for hypercholesterinemia treatment
|
№6 / 2017
|
|
T.Yu. Demidova, Ya.V. Pugovkina
Type 2 diabetes mellitus and cardiovascular diseases. Therapy that changes prognosis
|
№5 / 2017
|
|
Y.V. Konev, L.B. Lazebnik
Role of endotoxin of intestinal microbiota in the pathogenesis of atherosclerosis
|
№2 / 2015
|
Русский
